๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diffuse Large B-Cell Lymphoma
Clinical trial register · Japan

Diffuse Large B-Cell Lymphoma Trials in Japan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 2472 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
2472
Studies in scope
all four open statuses
1255
Recruiting now
open to new participants
347
Lead sponsors
across recruiting studies
Top sites
Fukuoka 10 Nagoya 6 Sapporo 6 Fukushima 5 Matsuyama 4
Narrow the registerReset
Recruitment status
Phase
Site location
Fukuoka10 Nagoya6 Sapporo6 Fukushima5 Matsuyama4
All 48 locations
Target enrolment
to

Diffuse Large B-Cell Lymphoma trials in Japan

14 of 2472 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Active, closed
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562Diffuse Large B-Cell Lymphoma
Tanabe Pharma Corporation
Phase 1/2
46
Nagoya, Kashiwa-shi, Fukuoka, Iizuka-shi, Fukushima, Gifu, Ota-shi, Sapporo
2023-01-30
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
290
Sapporo, Isehara, Tsu, Hirakata, Bunkyo, Minato, Chลซล, Fukuoka
2022-01-14
Active, closed
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Diffuse Large B-cell Lymphoma
Incyte Corporation
Phase 3
899
Fukuoka, Gifu, Ibaraki, Isehara, Kagoshima, Nagoya, Narita-shi, Okayama
2021-05-11
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
AstraZeneca
Phase 1
226
Chลซลku, Kลtoku, Nagoya, Yamagata
2021-03-02
Active, closed
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494Diffuse Large B-cell Lymphoma
Genmab
Phase 3
483
Fukuoka, Fukushima, Fukuyama, Hokkaido, Kashiwa, Kyoto, Matsuyama, Mie
2021-01-13
Active, closed
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
NCT04661007Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
Incyte Biosciences Japan GK
Phase 1/2
72
Aichi, Chiba, Fukui, Fukuoka, Hyลgo, Kanagawa, Kลtoku, Kumamoto-ken
2020-12-15
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 3
611
Chiba, Chลซลku, Fukuoka, Itabashi-ku, Kahoku-gun, Kashiwa, Kobe, Kลtoku
2020-10-08
Active, closed
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
Genmab
Phase 1/2
78
Sendai, Aichi, Chiba, Ehime, Fukuoka, Fukushima, Kagoshima, Kyoto
2020-08-20
Recruiting
Study of Out of Specification for Tisagenlecleucel
NCT04094311B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Novartis Pharmaceuticals
Phase 3
200
Nagoya, Tลon, Gifu, Sapporo, Kobe, Nishinomiya, Tsukuba, Kita-gun
2019-11-21
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
Phase 1/2
217
Sapporo, Bunkyo Ku, Fukuoka
2019-06-26
Active, closed
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
NCT03681535Diffuse Large B Cell Lymphoma
Duke University
Not applicable
243
Tokyo
2019-02-13
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-japan/condition/diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,472 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Diffuse Large B-Cell Lymphoma.

How many Diffuse Large B-Cell Lymphoma trials are recruiting in Japan?

3 of the 14 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B-Cell Lymphoma), 14 studies
PhaseStudiesRecruitingShare
Phase 37250%
Phase 1/24028.6%
Not applicable107.1%
Phase 1107.1%
Phase 2/3117.1%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B-Cell Lymphoma)
Lead sponsorStudiesRecruiting
Genmab40
Merck Sharp & Dohme LLC22
Novartis Pharmaceuticals21
Acerta Pharma BV10
AstraZeneca10
Duke University10
Incyte Biosciences Japan GK10
Incyte Corporation10
Tanabe Pharma Corporation10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.